ArticleNeuromolecular medicine2025
SAT1 Knockdown Decreases Glutamate-Induced Oxidative Stress, Ferroptosis, and Apoptosis in HT22 Cells via Activating the Nrf2/ARE Pathway.
Article in Neuromolecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glutamate toxicity is involved in the pathogenesis of neurological disorders, including epilepsy. Here we aimed to investigate the roles of Spermidine/spermine N1-acetyltransferase 1 (SAT1) in regulating glutamate-induced oxidative stress, ferroptosis, and apoptosis in mouse hippocampal HT22 cells. The results indicated that SAT1 expression was upregulated in mice with epilepsy and glutamate-stimulated HT22 cells. Knockdown of SAT1 exhibited antioxidant activity in glutamate-stimulated HT22 cells, as evidenced by increased activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), and decreased reactive oxygen species (ROS) production and malondialdehyde (MDA) content. SAT1 knockdown upregulated the expression of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), downregulated acyl-CoA synthetase long-chain family member 4 (ACSL4) expression, and reduced the Fe2+ level in glutamate-stimulated HT22 cells, suggesting that SAT1 knockdown reduced ferroptosis in glutamate-stimulated HT22 cells. SAT1 knockdown also decreased the apoptosis rate, caspase-3 activity, and Bcl2-associated X protein (Bax) expression, and increased B-cell leukemia/lymphoma 2 (Bcl-2) expression in glutamate-stimulated HT22 cells. Additionally, SAT1 knockdown reversed the inactivation of nuclear factor-erythroid 2 related factor 2 (Nrf2)/antioxidant response element (ARE) pathway in glutamate-stimulated HT22 cells. Nrf2 knockdown attenuated the effects of SAT1 knockdown on glutamate-induced oxidative stress, ferroptosis, and apoptosis. In conclusion, these findings indicate that SAT1 knockdown prevents glutamate-induced oxidative stress, ferroptosis, and apoptosis in HT22 cells by activating the Nrf2/ARE pathway.
Indexed as
Identifiers
41460412What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.